G1 Therapeutics Stock Today

GTHX Stock  USD 4.32  0.15  3.36%   

Performance

9 of 100

 
Low
 
High
OK

Odds Of Distress

Over 73

 
100  
 
Zero
High
G1 Therapeutics is trading at 4.32 as of the 29th of March 2024; that is -3.36 percent decrease since the beginning of the trading day. The stock's open price was 4.47. G1 Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for G1 Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of April 2022 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of May 2017
Category
Healthcare
Classification
Health Care
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. The company has 52.2 M outstanding shares of which 2.69 M shares are currently shorted by private and institutional investors with about 2.21 trading days to cover. More on G1 Therapeutics

GTHX Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. G1 Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding G1 Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorMark Velleca
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering G1 Therapeutics report their recommendations after researching G1 Therapeutics' financial statements, talking to executives and customers, or listening in on G1 Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering G1 Therapeutics. The GTHX consensus assessment is calculated by taking the average forecast from all of the analysts covering G1 Therapeutics.
G1 Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to G1 Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand G1 Therapeutics' financial leverage. It provides some insight into what part of G1 Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on G1 Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how G1 Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
G1 Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist G1 Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, G1 Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like G1 Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GTHX to invest in growth at high rates of return. When we think about G1 Therapeutics' use of debt, we should always consider it together with cash and equity.

Capital Expenditures

0.0
G1 Therapeutics (GTHX) is traded on NASDAQ Exchange in USA. It is located in 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709 and employs 100 people. G1 Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 226.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate G1 Therapeutics's market, we take the total number of its shares issued and multiply it by G1 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. G1 Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.2 M outstanding shares of which 2.69 M shares are currently shorted by private and institutional investors with about 2.21 trading days to cover. G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37.
Check G1 Therapeutics Probability Of Bankruptcy
Ownership Allocation
G1 Therapeutics shows a total of 52.2 Million outstanding shares. 30% of G1 Therapeutics outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check GTHX Ownership Details

GTHX Stock Price Odds Analysis

Based on a normal probability distribution, the odds of G1 Therapeutics jumping above the current price in 90 days from now is about 10.7%. The G1 Therapeutics probability density function shows the probability of G1 Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 6.9718. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, G1 Therapeutics will likely underperform. Additionally, g1 Therapeutics has an alpha of 0.2775, implying that it can generate a 0.28 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 4.32HorizonTargetOdds Above 4.32
89.26%90 days
 4.32 
10.70%
Based on a normal probability distribution, the odds of G1 Therapeutics to move above the current price in 90 days from now is about 10.7 (This G1 Therapeutics probability density function shows the probability of GTHX Stock to fall within a particular range of prices over 90 days) .

GTHX Stock Institutional Holders

Institutional Holdings refers to the ownership stake in G1 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of G1 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing G1 Therapeutics' value.
InstituionRecorded OnShares
Bank Of America Corp2023-12-31
279.5 K
Simplex Trading, Llc2023-12-31
233.6 K
Connor Clark & Lunn Inv Mgmt Ltd2023-12-31
192.1 K
Needham Investment Management, Llc2023-12-31
180 K
Level Four Advisory Services, Llc2023-12-31
178.6 K
Morgan Stanley - Brokerage Accounts2023-12-31
170.1 K
Two Sigma Investments Llc2023-12-31
162.1 K
State Street Corporation2023-12-31
161.1 K
Xtx Topco Ltd2023-12-31
157.2 K
Vanguard Group Inc2023-12-31
M
Susquehanna International Group, Llp2023-12-31
1.6 M
View G1 Therapeutics Diagnostics

G1 Therapeutics Historical Income Statement

G1 Therapeutics Income Statement is one of the three primary financial statements used for reporting GTHX's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of G1 Therapeutics revenue and expense. G1 Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, G1 Therapeutics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 86.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 291.2 K in 2024. View More Fundamentals

GTHX Stock Against Markets

Picking the right benchmark for G1 Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in G1 Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for G1 Therapeutics is critical whether you are bullish or bearish towards G1 Therapeutics at a given time. Please also check how G1 Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in G1 Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

G1 Therapeutics Corporate Directors

G1 Therapeutics corporate directors refer to members of a G1 Therapeutics board of directors. The board of directors generally takes responsibility for the G1 Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of G1 Therapeutics' board members must vote for the resolution. The G1 Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Andrew WittyDirectorProfile
Glenn MuirIndependent DirectorProfile
Garry NicholsonIndependent DirectorProfile
Tyrell RiversIndependent DirectorProfile

How to buy GTHX Stock?

Before investing in G1 Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in G1 Therapeutics. To buy G1 Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of G1 Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase G1 Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located G1 Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased G1 Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as G1 Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.

Already Invested in G1 Therapeutics?

The danger of trading G1 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of G1 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than G1 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile G1 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether G1 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of G1 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of G1 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on G1 Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.
Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for GTHX Stock analysis

When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bonds Directory
Find actively traded corporate debentures issued by US companies
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Global Correlations
Find global opportunities by holding instruments from different markets
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.93)
Revenue Per Share
1.595
Quarterly Revenue Growth
0.451
Return On Assets
(0.16)
Return On Equity
(0.92)
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.